// Endocrine System - Drugs
// Auto-generated from modularize-data.js

const drugs = [

    {
        "id": "insulin-lispro",
        "name": "Insulin Lispro",
        "pharmacologicClass": "insulin",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Replaces endogenous insulin, promotes glucose uptake and storage.",
        "features": "Rapid-acting (15 min onset).",
        "clinicalChoice": "Mealtime coverage, rapid correction.",
        "indications": [
            "Type 1 Diabetes",
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Hypoglycemia"
        ],
        "sideEffects": [
            "Hypoglycemia",
            "Weight gain",
            "Injection site reactions"
        ],
        "interactions": "Beta-blockers mask hypoglycemia symptoms.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "insulin-regular",
        "name": "Insulin Regular",
        "pharmacologicClass": "insulin",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Replaces endogenous insulin, promotes glucose uptake and storage.",
        "features": "Short-acting (30 min onset).",
        "clinicalChoice": "Mealtime coverage, DKA treatment.",
        "indications": [
            "Type 1 Diabetes",
            "Type 2 Diabetes",
            "DKA"
        ],
        "contraindications": [
            "Hypoglycemia"
        ],
        "sideEffects": [
            "Hypoglycemia",
            "Weight gain",
            "Injection site reactions"
        ],
        "interactions": "Beta-blockers mask hypoglycemia symptoms.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "insulin-nph",
        "name": "Insulin NPH",
        "pharmacologicClass": "insulin",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Replaces endogenous insulin, promotes glucose uptake and storage.",
        "features": "Intermediate-acting (2-4 hr onset).",
        "clinicalChoice": "Basal insulin coverage.",
        "indications": [
            "Type 1 Diabetes",
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Hypoglycemia"
        ],
        "sideEffects": [
            "Hypoglycemia",
            "Weight gain",
            "Injection site reactions"
        ],
        "interactions": "Beta-blockers mask hypoglycemia symptoms.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "insulin-glargine",
        "name": "Insulin Glargine",
        "pharmacologicClass": "insulin",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Replaces endogenous insulin, promotes glucose uptake and storage.",
        "features": "Long-acting (24 hr duration).",
        "clinicalChoice": "Once-daily basal insulin.",
        "indications": [
            "Type 1 Diabetes",
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Hypoglycemia"
        ],
        "sideEffects": [
            "Hypoglycemia",
            "Weight gain",
            "Injection site reactions"
        ],
        "interactions": "Beta-blockers mask hypoglycemia symptoms.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "metformin",
        "name": "Metformin",
        "pharmacologicClass": "biguanides",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Decrease hepatic glucose production, increase insulin sensitivity.",
        "features": "First-line therapy, weight neutral.",
        "clinicalChoice": "Initial T2DM treatment, PCOS.",
        "indications": [
            "Type 2 Diabetes",
            "PCOS"
        ],
        "contraindications": [
            "Renal Impairment",
            "Heart Failure",
            "Alcohol Abuse"
        ],
        "sideEffects": [
            "GI upset",
            "Lactic acidosis (rare)",
            "B12 deficiency"
        ],
        "interactions": "Contrast agents increase lactic acidosis risk.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "glipizide",
        "name": "Glipizide",
        "pharmacologicClass": "sulfonylureas",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Stimulate insulin release from pancreatic beta cells.",
        "features": "Short-acting, liver metabolism.",
        "clinicalChoice": "T2DM when metformin insufficient.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Diabetic Ketoacidosis"
        ],
        "sideEffects": [
            "Hypoglycemia",
            "Weight gain",
            "SIADH"
        ],
        "interactions": "Sulfonamides potentiate effects.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "glyburide",
        "name": "Glyburide",
        "pharmacologicClass": "sulfonylureas",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Stimulate insulin release from pancreatic beta cells.",
        "features": "Long-acting, higher hypoglycemia risk.",
        "clinicalChoice": "T2DM, avoid in elderly.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Renal Impairment"
        ],
        "sideEffects": [
            "Hypoglycemia",
            "Weight gain",
            "SIADH"
        ],
        "interactions": "Sulfonamides potentiate effects.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "glimepiride",
        "name": "Glimepiride",
        "pharmacologicClass": "sulfonylureas",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Stimulate insulin release from pancreatic beta cells.",
        "features": "Once-daily dosing.",
        "clinicalChoice": "T2DM with compliance issues.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Diabetic Ketoacidosis"
        ],
        "sideEffects": [
            "Hypoglycemia",
            "Weight gain",
            "SIADH"
        ],
        "interactions": "Sulfonamides potentiate effects.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "repaglinide",
        "name": "Repaglinide",
        "pharmacologicClass": "meglitinides",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Non-sulfonylurea insulin secretagogue. Binds to SUR1 receptor on ATP-sensitive K+ channels in pancreatic beta cells (different binding site than sulfonylureas) → closes K+ channels → membrane depolarization → Ca²⁺ influx → rapid insulin granule exocytosis. Rapid onset and short duration of action.",
        "features": "Rapid-acting insulin secretagogue, taken with meals. More potent meglitinide.",
        "clinicalChoice": "Type 2 Diabetes (as monotherapy or combination with metformin or TZDs)",
        "indications": [
            "Type 2 Diabetes (as monotherapy or combination with metformin or TZDs)"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Diabetic ketoacidosis",
            "Gemfibrozil use (severe drug interaction - CONTRAINDICATED)",
            "Severe hepatic impairment"
        ],
        "sideEffects": [
            "Hypoglycemia (5-10%, lower than sulfonylureas)",
            "Weight gain (1-2 kg, less than sulfonylureas)",
            "Upper respiratory tract infection",
            "Headache",
            "Diarrhea"
        ],
        "interactions": "CYP3A4 and CYP2C8 interactions. Gemfibrozil CONTRAINDICATED - increases repaglinide AUC by 8-fold.",
        "interactionDetails": "GEMFIBROZIL: CONTRAINDICATED - increases repaglinide AUC by 8-fold via CYP2C8 inhibition → severe prolonged hypoglycemia. DO NOT use together.",
        "pageType": "drug"
    },
    {
        "id": "nateglinide",
        "name": "Nateglinide",
        "pharmacologicClass": "meglitinides",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Non-sulfonylurea insulin secretagogue derived from D-phenylalanine. Binds to SUR1 receptor on ATP-sensitive K+ channels in pancreatic beta cells → closes K+ channels → depolarization → Ca²⁺ influx → rapid insulin release. Fastest onset of all meglitinides.",
        "features": "Ultra-rapid onset, shortest duration. Derived from amino acid D-phenylalanine. Less potent than repaglinide.",
        "clinicalChoice": "Type 2 Diabetes (as monotherapy or combination with metformin or TZDs)",
        "indications": [
            "Type 2 Diabetes (as monotherapy or combination with metformin or TZDs)"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Diabetic ketoacidosis"
        ],
        "sideEffects": [
            "Hypoglycemia (less common than repaglinide or sulfonylureas)",
            "Weight gain (minimal, 0.5-1 kg)",
            "Upper respiratory infection",
            "Diarrhea",
            "Dizziness"
        ],
        "interactions": "CYP2C9 inhibitors (fluconazole): increase nateglinide levels slightly (monitor glucose)",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "pioglitazone",
        "name": "Pioglitazone",
        "pharmacologicClass": "thiazolidinediones",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "PPAR-γ agonists, increase insulin sensitivity in muscle and fat.",
        "features": "Improves insulin sensitivity.",
        "clinicalChoice": "T2DM with insulin resistance.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Heart Failure",
            "Bladder Cancer History"
        ],
        "sideEffects": [
            "Weight gain",
            "Fluid retention",
            "Heart failure",
            "Bone fractures"
        ],
        "interactions": "CYP2C8 inhibitors increase levels.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "rosiglitazone",
        "name": "Rosiglitazone",
        "pharmacologicClass": "thiazolidinediones",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "PPAR-γ agonist → increases insulin sensitivity in muscle and adipose tissue.",
        "features": "REMOVED FROM MARKET (2010) due to cardiovascular risk.",
        "clinicalChoice": "NOT AVAILABLE - removed from US market in 2010 due to increased risk of myocardial infarction and cardiovascular death.",
        "indications": [
            "Previously: Type 2 Diabetes (NOW WITHDRAWN FROM MARKET)"
        ],
        "contraindications": [
            "DRUG WITHDRAWN FROM MARKET",
            "Historical contraindications: Heart failure, liver disease"
        ],
        "sideEffects": [
            "Weight gain",
            "Edema",
            "Fluid retention",
            "Myocardial infarction (increased risk - reason for market withdrawal)",
            "Cardiovascular death",
            "Heart failure",
            "Bone fractures"
        ],
        "interactions": "Historical: CYP2C8/2C9 interactions similar to pioglitazone",
        "interactionDetails": "REMOVED FROM MARKET: Increased risk of myocardial infarction and cardiovascular events led to FDA restriction in 2010 and subsequent market withdrawal.",
        "pageType": "drug"
    },
    {
        "id": "sitagliptin",
        "name": "Sitagliptin",
        "pharmacologicClass": "dpp-4-inhibitors",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Inhibit dipeptidyl peptidase-4, increase incretin levels.",
        "features": "Weight neutral, low hypoglycemia risk.",
        "clinicalChoice": "T2DM add-on therapy.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Diabetic Ketoacidosis"
        ],
        "sideEffects": [
            "Upper respiratory infections",
            "Headache",
            "Pancreatitis (rare)"
        ],
        "interactions": "Few significant interactions.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "linagliptin",
        "name": "Linagliptin",
        "pharmacologicClass": "dpp-4-inhibitors",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Inhibit dipeptidyl peptidase-4, increase incretin levels.",
        "features": "Hepatic elimination, safe in renal disease.",
        "clinicalChoice": "T2DM with kidney disease.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Type 1 Diabetes"
        ],
        "sideEffects": [
            "Upper respiratory infections",
            "Headache",
            "Pancreatitis (rare)"
        ],
        "interactions": "Few significant interactions.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "exenatide",
        "name": "Exenatide",
        "pharmacologicClass": "glp-1-receptor-agonists",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Mimic incretin hormones, glucose-dependent insulin release.",
        "features": "Twice-daily injection, weight loss.",
        "clinicalChoice": "T2DM with obesity.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Gastroparesis"
        ],
        "sideEffects": [
            "Nausea",
            "Vomiting",
            "Diarrhea",
            "Pancreatitis risk"
        ],
        "interactions": "Delay gastric emptying, affect oral drug absorption.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "liraglutide",
        "name": "Liraglutide",
        "pharmacologicClass": "glp-1-receptor-agonists",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Mimic incretin hormones, glucose-dependent insulin release.",
        "features": "Once-daily, cardiovascular benefits.",
        "clinicalChoice": "T2DM with CV risk.",
        "indications": [
            "Type 2 Diabetes",
            "Obesity"
        ],
        "contraindications": [
            "MTC History",
            "MEN 2"
        ],
        "sideEffects": [
            "Nausea",
            "Vomiting",
            "Diarrhea",
            "Pancreatitis risk"
        ],
        "interactions": "Delay gastric emptying, affect oral drug absorption.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "empagliflozin",
        "name": "Empagliflozin",
        "pharmacologicClass": "sglt2-inhibitors",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Block sodium-glucose cotransporter-2 in kidneys, increase glucose excretion.",
        "features": "Cardiovascular and renal benefits.",
        "clinicalChoice": "T2DM with heart failure or CKD.",
        "indications": [
            "Type 2 Diabetes",
            "Heart Failure"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Severe Renal Impairment"
        ],
        "sideEffects": [
            "UTIs",
            "Genital mycotic infections",
            "DKA risk",
            "Dehydration"
        ],
        "interactions": "Diuretics increase dehydration risk.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "canagliflozin",
        "name": "Canagliflozin",
        "pharmacologicClass": "sglt2-inhibitors",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Block sodium-glucose cotransporter-2 in kidneys, increase glucose excretion.",
        "features": "May reduce CV events.",
        "clinicalChoice": "T2DM with established CVD.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Severe Renal Impairment",
            "Lower Limb Amputation History"
        ],
        "sideEffects": [
            "UTIs",
            "Genital mycotic infections",
            "DKA risk",
            "Dehydration"
        ],
        "interactions": "Diuretics increase dehydration risk.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "pramlintide",
        "name": "Pramlintide",
        "pharmacologicClass": "amylin-analogs",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Synthetic analog of amylin, a hormone co-secreted with insulin from pancreatic beta cells. Slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety via central mechanisms.",
        "features": "Only amylin analog available. Adjunct to insulin therapy.",
        "clinicalChoice": "For patients on mealtime insulin who have inadequate glucose control despite optimal insulin therapy. Unique benefit of weight loss (3-4 kg average).",
        "indications": [
            "Type 1 Diabetes (as adjunct to mealtime insulin)",
            "Type 2 Diabetes (as adjunct to mealtime insulin)"
        ],
        "contraindications": [
            "Gastroparesis",
            "Hypoglycemia unawareness"
        ],
        "sideEffects": [
            "Nausea (60-70%, usually improves over 4 weeks)",
            "Vomiting",
            "Anorexia",
            "Headache",
            "Severe hypoglycemia (when not reducing insulin dose appropriately)"
        ],
        "interactions": "Insulin: increased hypoglycemia risk (reduce insulin dose by 50%). Drugs requiring rapid absorption: delayed by pramlintide.",
        "interactionDetails": "BLACK BOX: Severe hypoglycemia - must reduce mealtime insulin by 50% when starting pramlintide.",
        "pageType": "drug"
    },
    {
        "id": "acarbose",
        "name": "Acarbose",
        "pharmacologicClass": "alpha-glucosidase-inhibitors",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Reversibly inhibits alpha-glucosidase enzymes in small intestine brush border, delaying breakdown of complex carbohydrates into absorbable monosaccharides. Reduces postprandial glucose spikes.",
        "features": "Minimal systemic absorption (<2%). Acts locally in GI tract.",
        "clinicalChoice": "For patients with elevated postprandial glucose but acceptable fasting glucose. Particularly useful in Asian populations (high-carbohydrate diets).",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Inflammatory bowel disease (Crohn's, ulcerative colitis)",
            "Colonic ulceration",
            "Intestinal obstruction",
            "Chronic intestinal diseases with malabsorption",
            "Cirrhosis"
        ],
        "sideEffects": [
            "Flatulence (75% of patients - due to colonic fermentation of undigested carbs)",
            "Diarrhea (30%)",
            "Abdominal pain/cramping (20%)",
            "Elevated liver enzymes (rare, reversible)"
        ],
        "interactions": "Must take with FIRST BITE of meal. If hypoglycemia occurs, treat with GLUCOSE (not sucrose - acarbose blocks sucrose breakdown).",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "miglitol",
        "name": "Miglitol",
        "pharmacologicClass": "alpha-glucosidase-inhibitors",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Reversibly inhibits alpha-glucosidase enzymes in small intestine, delaying digestion and absorption of carbohydrates. Reduces postprandial glucose excursions.",
        "features": "Well absorbed systemically (unlike acarbose). Renally excreted unchanged.",
        "clinicalChoice": "Alternative to acarbose with similar efficacy and side effect profile. Avoid in renal impairment (systemically absorbed and renally excreted).",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Inflammatory bowel disease",
            "Colonic ulceration",
            "Intestinal obstruction",
            "Severe renal impairment (CrCl <25 mL/min)",
            "Chronic intestinal diseases with malabsorption"
        ],
        "sideEffects": [
            "Flatulence (70% - due to colonic fermentation)",
            "Diarrhea (30%)",
            "Abdominal pain (10-15%)"
        ],
        "interactions": "Must take with FIRST BITE of each meal. If hypoglycemia occurs, treat with GLUCOSE (not sucrose).",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "levothyroxine",
        "name": "Levothyroxine",
        "pharmacologicClass": "thyroid-hormones",
        "therapeuticClass": "thyroid-medications",
        "system": "endocrine-system",
        "mechanism": "Replace deficient thyroid hormones T4 and T3.",
        "features": "T4 replacement, converted to T3.",
        "clinicalChoice": "Hypothyroidism treatment.",
        "indications": [
            "Hypothyroidism",
            "Thyroid Cancer"
        ],
        "contraindications": [
            "Untreated Adrenal Insufficiency"
        ],
        "sideEffects": [
            "Hyperthyroid symptoms",
            "Arrhythmias",
            "Osteoporosis"
        ],
        "interactions": "Iron, calcium reduce absorption.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "liothyronine",
        "name": "Liothyronine",
        "pharmacologicClass": "thyroid-hormones",
        "therapeuticClass": "thyroid-medications",
        "system": "endocrine-system",
        "mechanism": "Replace deficient thyroid hormones T4 and T3.",
        "features": "T3 replacement, rapid onset.",
        "clinicalChoice": "Myxedema coma.",
        "indications": [
            "Severe Hypothyroidism",
            "Myxedema Coma"
        ],
        "contraindications": [
            "Untreated Adrenal Insufficiency"
        ],
        "sideEffects": [
            "Hyperthyroid symptoms",
            "Arrhythmias",
            "Osteoporosis"
        ],
        "interactions": "Iron, calcium reduce absorption.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "methimazole",
        "name": "Methimazole",
        "pharmacologicClass": "antithyroid-agents",
        "therapeuticClass": "thyroid-medications",
        "system": "endocrine-system",
        "mechanism": "Inhibit thyroid hormone synthesis.",
        "features": "Preferred agent, once-daily dosing.",
        "clinicalChoice": "Hyperthyroidism treatment.",
        "indications": [
            "Hyperthyroidism",
            "Graves Disease"
        ],
        "contraindications": [
            "Pregnancy (1st trimester)"
        ],
        "sideEffects": [
            "Agranulocytosis",
            "Hepatotoxicity",
            "Rash"
        ],
        "interactions": "Warfarin effects enhanced.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "propylthiouracil",
        "name": "Propylthiouracil",
        "pharmacologicClass": "antithyroid-agents",
        "therapeuticClass": "thyroid-medications",
        "system": "endocrine-system",
        "mechanism": "Inhibit thyroid hormone synthesis.",
        "features": "Blocks T4 to T3 conversion.",
        "clinicalChoice": "Pregnancy, thyroid storm.",
        "indications": [
            "Hyperthyroidism in Pregnancy",
            "Thyroid Storm"
        ],
        "contraindications": [
            "Severe Liver Disease"
        ],
        "sideEffects": [
            "Agranulocytosis",
            "Hepatotoxicity",
            "Rash"
        ],
        "interactions": "Warfarin effects enhanced.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "prednisone",
        "name": "Prednisone",
        "pharmacologicClass": "glucocorticoids",
        "therapeuticClass": "corticosteroids",
        "system": "endocrine-system",
        "mechanism": "Anti-inflammatory and immunosuppressive effects via genomic pathways.",
        "features": "Oral prodrug, converted to prednisolone. | Oral, intermediate-acting.",
        "clinicalChoice": "Inflammatory conditions, immunosuppression.",
        "indications": [
            "Allergic Reactions",
            "Asthma",
            "Autoimmune Disorders",
            "Inflammatory Diseases",
            "Rheumatoid Arthritis"
        ],
        "contraindications": [
            "Systemic Fungal Infections"
        ],
        "sideEffects": [
            "Hyperglycemia",
            "Osteoporosis",
            "Immunosuppression",
            "Adrenal suppression"
        ],
        "interactions": "CYP3A4 inducers/inhibitors affect levels.",
        "interactionDetails": "",
        "pageType": "drug",
        "pharmacologicClasses": [
            "glucocorticoids",
            "systemic-corticosteroids"
        ]
    },
    {
        "id": "dexamethasone",
        "name": "Dexamethasone",
        "pharmacologicClass": "glucocorticoids",
        "therapeuticClass": "corticosteroids",
        "system": "endocrine-system",
        "mechanism": "Anti-inflammatory and immunosuppressive effects via genomic pathways.",
        "features": "Long-acting, high potency. | Long-acting, potent, minimal mineralocorticoid activity.",
        "clinicalChoice": "Cerebral edema, severe inflammation.",
        "indications": [
            "Adrenal Insufficiency Testing",
            "Cerebral Edema",
            "Severe Asthma"
        ],
        "contraindications": [
            "Systemic Fungal Infections"
        ],
        "sideEffects": [
            "Hyperglycemia",
            "Osteoporosis",
            "Immunosuppression",
            "Adrenal suppression"
        ],
        "interactions": "CYP3A4 inducers/inhibitors affect levels.",
        "interactionDetails": "",
        "pageType": "drug",
        "pharmacologicClasses": [
            "glucocorticoids",
            "systemic-corticosteroids"
        ]
    },
    {
        "id": "fludrocortisone",
        "name": "Fludrocortisone",
        "pharmacologicClass": "mineralocorticoids",
        "therapeuticClass": "corticosteroids",
        "system": "endocrine-system",
        "mechanism": "Sodium retention and potassium excretion in distal nephron.",
        "features": "Oral mineralocorticoid replacement.",
        "clinicalChoice": "Adrenal insufficiency with salt wasting.",
        "indications": [
            "Primary Adrenal Insufficiency",
            "Orthostatic Hypotension"
        ],
        "contraindications": [
            "Systemic Fungal Infections",
            "Hypertension"
        ],
        "sideEffects": [
            "Hypertension",
            "Hypokalemia",
            "Fluid retention"
        ],
        "interactions": "NSAIDs reduce effectiveness.",
        "interactionDetails": "",
        "pageType": "drug"
    }

];export default drugs;
